MedTrace Logo

Scorpio NRG (eNeRGize) Cruciate Retaining (CR) Post-market International Outcome Study

NCT02524730 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 205

Last updated 2024-02-22

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to collect basic function, radiographic and patient satisfaction data for observation and analysis.

Conditions

  • Arthroplasty, Replacement, Knee

Interventions

DEVICE

Primary total knee replacement (Scorpio NRG CR Total Knee System)

Scorpio NRG CR Total Knee System

Sponsors & Collaborators

  • Stryker Orthopaedics

    lead INDUSTRY

Principal Investigators

  • Martin Krismer, Prof. · Medical University Innsbruck

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
40 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-05-18
Primary Completion
2020-02-10
Completion
2020-02-10
FDA Device
Yes

Countries

  • Austria
  • Germany
  • Netherlands
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02524730 on ClinicalTrials.gov